Director MR Imaging to Antaros Medical

Are you interested in an innovative company characterized by an entrepreneurial and inspiring spirit? A company, where you would be valued for your competence, ideas and creativity? A place, where relations and trust are keys to success and where we all value having fun while doing a meaningful job? If this sounds interesting, we may have the perfect offer for you.

At Antaros Medical, we are pioneering imaging methodologies, such as Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET), to design and deliver clinical studies for decision making and differentiation in drug development. We are specialized in cardiorenal and metabolic diseases (including NAFLD/NASH and chronic kidney disease) and oncology. We have a global network of partners and customers, including both large and small drug development companies, and we are a partner in several European research consortia, such as the Innovative Medicine Initiative (IMI) and COST. We are based in the BioVentureHub in Mölndal and in Uppsala Science Park, Sweden and recently, we opened a subsidiary in US.

Since we are growing, we are now looking for a Director MR Imaging - an exciting and diverse role at Antaros Medical. As a Director MR Imaging, you will be involved in the design of clinical trials ensuring the best MR methods are applied in our contract research studies and as part of our own R&D. Your main focus will be responsibility for setting up harmonized imaging protocols, selecting and qualifying the participating imaging sites, and training the Antaros Corelab on analysis methods.

You will join a group of imaging specialists with expertise in MR and PET, and you will be working closely with project managers, image analysts and software developers to deliver innovative imaging solutions to the pharmaceutical industry.

An important aspect of your job will be visiting imaging sites to set-up imaging protocols, which means you should be able to travel regularly, have good social skills and fluency in English. Preferably, you also have experience of working hands-on at the scanner. The job encourages interaction with new potential customers as part of the Antaros Medical sales strategy. Method development is a core activity at Antaros Medical, and scientific communication is an important channel to share our results. We therefore encourage scientific publishing and presenting on international scientific congresses.

You will have a scientific background in MR imaging. You drive your work independently but enjoy working in project teams from start to finish to achieve the goal. Experience in the pharmaceutical or medical technology industries is an advantage.

Your main responsibilities will be:

- Managing imaging aspects of clinical trials
- Developing analysis methods, training and certifying Corelab image analysts


Additional responsibilities could include:

- Communication with new customers, supporting sales and business development
- Scientific communication (writing publications and presenting research)


Requirements:

- A Ph.D. degree in a relevant field or comparable work experience
- Experience in Magnetic Resonance Imaging.
- Flexibility and ability to handle multiple tasks to meet deadlines while delivering high quality work in a dynamic environment.
- Demonstrated collaboration skills as well as a team-oriented approach to engage with colleagues and clients.


Preferred qualifications:

- Experience in abdominal imaging
- Good understanding of the physiological/pathology behind imaging endpoints
- Experience in scientific communication (publishing and presenting)
- Experience in GCP and clinical trials
- Experience in spectroscopic imaging


The position is based at our Uppsala or Mölndal offices in Sweden.

More information

For more information about the position, please contact Kerstin Heurling, Manager Imaging for projects and R&D, Kerstin.heurling@antarosmedical.com or +46722338634.

Please submit your application via this link with a short personal letter and your CV included, no later than March 1, 2020.